Review article · 2023 · Open access
Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
Rheumatology International, 43(3), 421–435 · Published 13 January 2023 · DOI 10.1007/s00296-022-05270-6
In brief
“Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies” is a 2023 review article by Chrysoula G. Gialouri and 4 co-authors, published in Rheumatology International. OpenAlex counts 39 citations as of 19 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Rheumatology International.
- Citations
- 39
- Most cited in
- 2026 (13)
- Field-weighted impact
- 1.31
- References
- 119
- Authors
- 5
Abstract
JAK inhibitors (JAKi) are new targeted-synthetic drugs, approved for various immune-mediated inflammatory diseases (IMIDs), including inflammatory arthritides (rheumatoid arthritis-RA, psoriatic arthritis-PsA, ankylosing spondylitis-AS) and ulcerative colitis (UC). JAKi have been associated with increased risk for herpes zoster (HZ), but the relative risk among different JAKi in these IMIDs remains unclear. We aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with the approved doses of tofacitinib (TOFA), baricitinib (BARI) or upadacitinib (UPA). PubMed, Embase, Scopus, Cochrane and Web-of-Science were searched up to 30 March 2022. Clinical trials and real-world studies (RWS) were included. Outcomes assessed were the incidence rate (/100 patient-years) or/and cumulative incidence of HZ. From 1710 records, 53 clinical trials and 25 RWS were included (RA: 54, PsA: 8, AS: 4, and UC: 12). In clinical trials, the HZ-incidence was higher in TOFA-treated patients with RA (2.2-7.1/100 patient-years) or UC (1.3-7.6/100 patient-years) compared to PsA (1.7/100 patient-years), and with higher doses of TOFA in UC (10 mg/twice daily: 3.2-7.6/100 patient-years vs. 5 mg/twice daily: 1.3-2.3/100 patient-years). Evidence for HZ-risk in JAKi-treated patients with AS and in UPA-treated patients was limited. The HZ-incidence between TOFA and BARI groups in 2 RA RWS did not differ significantly. Concomitant glucocorticoid, but not methotrexate, use in RA increased the HZ-risk. This systematic review showed higher HZ-risk in RA or UC than PsA patients treated with TOFA, in those treated with higher TOFA doses or with concomitant glucocorticoids. Preventive measures and monitoring of JAKi-treated patients with IMIDs are essential in daily practice.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Gialouri, C. G., Moustafa, S., Thomas, Κ., Hadziyannis, E. S., & Vassilopoulos, D. (2023). Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatology International, 43(3), 421–435. https://doi.org/10.1007/s00296-022-05270-6
MLA 9
Gialouri, Chrysoula G., et al. “Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.” Rheumatology International, vol. 43, no. 3, 2023, pp. 421–435. https://doi.org/10.1007/s00296-022-05270-6.
Chicago
Gialouri, Chrysoula G., Savvina Moustafa, Κonstantinos Thomas, Emilia S. Hadziyannis, and Dimitrios Vassilopoulos. 2023. “Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.” Rheumatology International 43 (3): 421–435. https://doi.org/10.1007/s00296-022-05270-6.
Harvard
Gialouri, C. G. et al. (2023) ‘Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies’, Rheumatology International, 43(3), pp. 421–435. doi:10.1007/s00296-022-05270-6.
IEEE
C. G. Gialouri, S. Moustafa, Κ. Thomas, E. S. Hadziyannis, and D. Vassilopoulos, “Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies,” Rheumatology International, vol. 43, no. 3, pp. 421–435, 2023, doi: 10.1007/s00296-022-05270-6.
BibTeX
@article{gialouri2023herpes,
title = {{Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies}},
author = {Gialouri, Chrysoula G. and Moustafa, Savvina and Thomas, Κonstantinos and Hadziyannis, Emilia S. and Vassilopoulos, Dimitrios},
journal = {Rheumatology International},
year = {2023},
volume = {43},
number = {3},
pages = {421--435},
doi = {10.1007/s00296-022-05270-6},
url = {https://doi.org/10.1007/s00296-022-05270-6}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 6 | |
| 2024 | 11 | |
| 2025 | 9 | |
| 2026 | 13 |
Its field-weighted citation impact is 1.31: it has been cited 1.31 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- herpes zoster
- JAK inhibitors
- tofacitinib
- baricitinib
- upadacitinib
- inflammatory arthritis
- rheumatoid arthritis
- psoriatic arthritis
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Gialouri, C. G., Moustafa, S., Thomas, Κ., Hadziyannis, E. S., & Vassilopoulos, D. (2023). Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatology International, 43(3), 421–435. https://doi.org/10.1007/s00296-022-05270-6
How many times has this paper been cited?
39 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Rheumatology International: sign in and open the PDF from this page.
Who wrote this paper?
Chrysoula G. Gialouri, Savvina Moustafa, Κonstantinos Thomas, Emilia S. Hadziyannis, Dimitrios Vassilopoulos.
What is the DOI of this paper?
10.1007/s00296-022-05270-6, permanently at https://doi.org/10.1007/s00296-022-05270-6. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.